Evaluating Observational and Propensity Matched Studies in Metastatic Castration Sensitive Prostate Cancer (mCSPC)

In this segment, Dr. Charles J. Ryan invites the panel to discuss how clinicians evaluate evidence from observational studies and propensity matched analyses in metastatic castration sensitive prostate cancer (mCSPC). Dr. Alan H. Bryce, Dr. Murilo De Almeida Luz, and Dr. Jayram explain that these study designs are often used when randomized clinical trial data are limited or unavailable. The panel highlights that observational and propensity matched studies can provide valuable insights into treatment outcomes, safety, and patient populations that may be underrepresented in clinical trials. At the same time, the physicians emphasize important limitations, including potential selection bias, residual confounding, and differences in baseline patient characteristics that may affect the interpretation of results. The discussion focuses on how clinicians critically evaluate these studies while recognizing their role in complementing randomized trial evidence. Overall, this segment highlights how multiple types of evidence contribute to informed clinical decision making in metastatic castration sensitive prostate cancer.